Concepedia

Na Li

NL

6

Publications

207

Citations

6

H-Index

2008

Active since

Affiliations

Bayer (Germany)(Current)

Bayer (United States)

Velocity Clinical Research (United States)

Indiana University – Purdue University Indianapolis

China Pharmaceutical University

Na Li is an author at Bayer (Germany) specializing in pulmonary vascular disease, medicine, and pharmacology.

ORCID

Top concepts

Publications per year

2008–2025

6

Publications

6

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

Rajiv Agarwal, Jennifer B. Green, Hiddo J.L. Heerspink et al. · New England Journal of Medicine · 2025 · 125 citations · Full text

CPU86017 and its isomers improve hypoxic pulmonary hypertension by attenuating increased ETA receptor expression and extracellular matrix accumulation

Na Li, De‐Zai Dai, Yin Dai · Naunyn-Schmiedeberg s Archives of Pharmacology · 2008 · 22 citations

, , +10

The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension

Tobias Gessler, Hossein Ardeschir Ghofrani, Matthias Held et al. · Pulmonary Circulation · 2017 · 22 citations · Full text

, , +16

CPU0213, A NON‐SELECTIVE ET<sub>A</sub>/ET<sub>B</sub> RECEPTOR ANTAGONIST, IMPROVES PULMONARY ARTERIOLAR REMODELING OF MONOCROTALINE‐INDUCED PULMONARY HYPERTENSION IN RATS

Bing Cui, Yusi Cheng, De‐Zai Dai et al. · Clinical and Experimental Pharmacology and Physiology · 2009 · 16 citations

COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics

Rajiv Agarwal, Jennifer B. Green, Hiddo J.L. Heerspink et al. · Nephrology Dialysis Transplantation · 2025 · 12 citations · Full text

Rows per page

1–5 of 6